| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8442829 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
The dose and schedule recommended for further study with SNX-5422 is 100Â mg/m2 QOD 3Â weeks on/1Â week off based on improved tolerability and preliminary evidence of clinical activity.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jeffrey R. Infante, Glen J. Weiss, Suzanne Jones, Raoul Tibes, Todd M. Bauer, Johanna C. Bendell, James M. Jr., Daniel D. Von Hoff, Howard A. III, Everardus O. Orlemans, Ramesh K. Ramanathan,